CTOs on the Move

Axogen Incorporated

www.axogeninc.com

 
Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.axogeninc.com
  • 13631 Progress Boulevard Suite 400
    Alachua, FL USA 32615
  • Phone: 386.462.6800

Executives

Name Title Contact Details

Funding

Axogen Incorporated raised $17.5M on 08/27/2015

Similar Companies

Revolution Medicines

REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Asthmatx

Asthmatx is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

BioInquire

BioInquire is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.